Cardiac Marker Testing Market Assessment, By Product Type [Reagents and Kits, Instruments], By Indication [Myocardial Infraction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Ischemia], By Biomarker Type [Troponin I and T, Creatine

Cardiac Marker Testing Market Assessment, By Product Type [Reagents and Kits, Instruments], By Indication [Myocardial Infraction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Ischemia], By Biomarker Type [Troponin I and T, Creatine Kinase-MB, Brain Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein, Others], By Type of Testing [Laboratory Testing, Point of care Testing Facilities], By End-user [Hospital Laboratories, Research Contract Laboratories, Academic Institutes, Point-of-Care-Testing Facilities, Others], By Region, Opportunities and Forecast, 2017-2031F

Global cardiac marker testing market is projected to witness a CAGR of 8.6% during the forecast period 2024-2031F, growing from USD 6.07 billion in 2023 to USD 11.74 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. There is a significant need for cardiac marker testing due to the increased prevalence of cardiovascular conditions such as congestive heart failure and heart attacks.

Cardiac markers include a broad spectrum of diagnostic tests and instruments targeted at identifying particular biomarkers associated with cardiac health and are essential to the diagnosis and treatment of heart-related disorders. Due to this, physicians and healthcare professionals depend more on these tests to monitor their heart status, assess risk, and identify early. Furthermore, the field of cardiac marker testing has undergone a radical change due to technological improvements. Novel approaches and enhanced testing protocols augment the precision and velocity of diagnosis, permitting expeditious and efficient patient handling.

Furthermore, advancing highly sensitive cardiac biomarkers is helping professionals identify cardiac problems early, ultimately leading to better patient outcomes.For instance, Abbott Laboratories introduced the ARCHITECT Myxovirus Multiplex Assay in February 2024. The assay can simultaneously detect many respiratory viruses, such as influenza A and B, respiratory syncytial virus (RSV), and parainfluenza viruses. The test can help medical professionals differentiate between respiratory infections and heart problems, which can occasionally present with similar symptoms.

Rising Incidences of Cardiovascular Diseases

The rapid expansion of the global market for cardiac marker testing is mostly due to the increased frequency of cardiovascular disorders. Heart attacks, strokes, and congestive heart failure are examples of cardiovascular disorders, which remain the world's top causes of death and morbidity. Cardiac marker testing is becoming integral to modern healthcare due to the tremendous demand for growing health concerns. The incidence of cardiovascular diseases is rising as the world's population ages and lifestyle ambiguities such as poor diets, sedentary habits, and elevated stress levels proliferate. Notably, the need for cardiac marker testing has increased due to the aging population's increased susceptibility to heart-related conditions. Identifying and treating cardiac abnormalities as soon as possible is critical because early identification and treatment can greatly improve the quality of life. Due to increased awareness, people are more proactive in managing their heart health, increasing the need for cardiac marker testing for early diagnosis and risk assessment. Technologies for cardiac marker testing are being purchased by healthcare systems and organizations, who include them in their preventative healthcare programs.

According to a report by WHO, globally, cardiovascular diseases (CVDs) account for 17.9 million deaths annually, making them the leading cause of death. Heart and blood vessel illnesses together referred to as CVDs include rheumatic heart disease, coronary heart disease, and cerebrovascular disease. Heart attacks and strokes account for more than four out of every five deaths from CVD, and one-third of these deaths happen too soon among those under the age of 70.

Furthermore, the COVID-19 pandemic has brought attention to the importance of heart health. The virus has been associated with a higher risk of cardiovascular problems, which emphasizes the importance of cardiac marker testing. Global health systems are increasingly emphasizing detecting cardiac problems in COVID-19 patients, highlighting the importance of quick, precise, and trustworthy diagnostic testing.

Technological Advancements to Increase Global Cardiac Marker Testing Market

Technological developments are essential for driving the growth of the global cardiac marker testing market to unprecedented heights, stimulating creativity, and changing the face of cardiac diagnostics. The sensitivity, accuracy, and efficiency of cardiac marker testing have improved dramatically due to these developments, greatly improving the market outlook. Developing and implementing very sensitive cardiac biomarkers is a noteworthy progression in this domain. These biomarkers enable the early and accurate detection of heart disorders by identifying even the smallest amounts of cardiac-specific proteins in the blood. For instance, troponin is a highly sensitive marker for myocardial injury that makes it possible to detect cardiac problems early. These advancements are essential for spotting cardiac issues long before symptoms, allowing prompt intervention and better patient outcomes.

Furthermore, technological advancements have made point-of-care testing (POCT) for cardiac markers possible. POCT devices make on-site testing quick and easy, eliminating the need for laborious laboratory analysis. These portable gadgets are very helpful when prompt diagnosis is essential in emergency rooms and critical care settings. POCT has expedited treatment decisions and shortened turnaround times, which has improved patient care while making healthcare systems more cost-effective.

The fields of cardiac marker testing have benefited greatly from advances in genetic testing and molecular diagnosis. These methods allow identifying genetic alterations and indicators linked to cardiovascular disorders. Customized treatment plans can be created by determining a person's genetic susceptibility to cardiac problems. It allows for the customization of therapies to the specific genetic composition of each patient. The degree of customization lowers the dangers connected with needless medical treatments while simultaneously improving patient care. Alongside these developments, the specificity and multiplexing power of cardiac marker tests have been significantly improved. It implies that a single test can provide a more thorough profile of a patient's cardiac health for clinicians, negating the need for numerous independent analyses. Furthermore, incorporating machine learning and artificial intelligence into cardiac marker testing may improve diagnostic precision and offer prediction insights, resulting in more proactive and focused patient care.

PocDoc, a prominent provider of personal diagnostics and digital health platforms, announced the launch of the world's first smartphone-based cardiovascular exam in January 2022. The test will first be available to pharmacies, private healthcare providers, and NHS providers. The new test will cover all five market lipid panels, and the company projects by lowering the number of staff members needed, their system would save millions of dollars annually.

Increasing Demand for Troponin

The market for cardiac marker testing is experiencing significant growth due to the innovative trend of high-sensitivity cardiac biomarkers. These sophisticated biomarkers, particularly high-sensitivity troponin assays, have dramatically improved cardiac diagnostic tests' sensitivity, accuracy, and clinical usefulness, completely changing the field. The high-sensitivity cardiac biomarkers, which can identify minute amounts of cardiac-specific proteins in the blood, are one of the main factors influencing the development. High-sensitivity troponin assays are far more sensitive than their conventional counterparts when identifying myocardial injury or stress, which may have limited sensitivity. It implies that medical professionals can identify cardiac problems long before symptoms appear, enabling prompt and accurate treatment. When diagnosing an acute myocardial infarction (heart attack), the significance of high-sensitivity cardiac biomarkers is especially noticeable. These indicators allow for prompt and precise diagnosis of minute and clinically important changes in troponin levels.

Early identification is essential as it allows quicker medical intervention, which can improve patient outcomes and lessen the severity of heart muscle damage. High-sensitivity cardiac biomarkers are essential for prognostication and risk assessment. They aid physicians in assessing the probability of upcoming cardiovascular events by offering more accurate and detailed information regarding a patient's cardiac health. This makes it easier to customize treatment programs and take preventative measures for people who are at risk, leading to more effective and individualized patient care. In addition to increasing diagnostic accuracy, the increasing use of high-sensitivity cardiac biomarkers has allowed medical professionals to make decisions quickly and with greater knowledge. Consequently, these biomarkers are propelling improvements in patient management and care.

In September 2022, Agilus Diagnostics Ltd., one of the diagnostic laboratory chains in India, introduced ""Heart Assure,"" a specialized high-sensitivity Troponin I (hsTnI) test that may forecast the risk of a cardiac event in the target group. By delivering a heart health risk score and estimating the likelihood of a future cardiac event, the hsTnI is a straightforward blood test that can detect even minute levels of Troponin I (picogram/ml) in the blood and accurately forecast a cardiac event or injury.

North America to Dominate Global Cardiac Marker Testing Market Share

In the forecasted period, North America is anticipated to lead the global market for cardiac marker analyzers. Sedentary lifestyles, inactivity, poor diets, and stress are the main causes of the increase in the prevalence of many cardiovascular conditions, including atrial fibrillation, coronary artery disease, and strokes. The rise of the market is mostly attributed to the United States, among other regional countries. For instance, according to the January 2022 update from Cedars-Sinai, the most common type of heart surgery is coronary artery bypass graft surgery (CABG), known as coronary artery bypass or bypass surgery, with over 300,000 successful bypass surgeries performed annually in the United States. Furthermore, according to the CDC's July 2022 report, 20.1 million adults in the United States aged 20 and older have coronary heart disease, making it the most prevalent type of heart disease. Furthermore, the source states that approximately 805,000 Americans experience a heart attack each year and that a heart attack occurs every 40 seconds. Therefore, the high prevalence of cardiovascular disorders drives the need for sophisticated diagnostic tools to enable more effective treatment, which in turn fuels the market for cardiac markers. It is anticipated that regional market expansion will be boosted by the increasing demand for cardiac marker analyzers.

Future Market Scenario (2024 – 2031F)

One of the main factors contributing to the anticipated growth of the cardiac marker testing market is the increasing prevalence of cardiovascular diseases. The rising geriatric population is a factor that will propel market growth in the future. Given that technology is advancing, we can expect innovative technology in the market as well. Players in the market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, in July 2022, Siemens Healthcare Private Limited launched the Atellica CI 1900 Analyzer, a clinical chemistry and immunoassay testing instrument, as well as a reduced volume version of its commercially available Atellica clinical chemistry and immunoassay testing solution at the Annual Scientific Meeting and Clinical Lab Expo.

Key Players Landscape and Outlook

Several companies are expanding their business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launch of newly developed cardiac marker testers, to help researchers to bring their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are a few ways through which they are trying to achieve the same.

Siemens Healthcare Private Limited’s Atellica CH SOAPS Assay, a cutting-edge test that finds creatine kinase-MB (CK-MB), a crucial cardiac marker, was approved by the FDA in February 2023. The Atellica CH immunoassay analyzer, which offers faster turnaround times and more efficient workflow, is specifically designed for this assay.

The BD Vacutainer Troponin I Ultra test is the first and only FDA-approved point-of-care troponin test for diagnosing acute myocardial infarction (AMI). Becton, Dickinson and Company announced 2023 that it had received FDA approval for the test to be used in point-of-care settings.